Most people who stop an antidepressant recover their sexual function within weeks. A minority do not. When reduced desire, blunted orgasm, or numbness in the genital area persists for months after the last dose, the condition is called post-SSRI sexual dysfunction (PSSD). It has diagnostic criteria published in 2022, regulatory recognition in Europe and Canada, and no established treatment. This article covers what is known, what is disputed, and what has to be excluded before the label is applied.
What PSSD is, and what it is not
PSSD describes sexual dysfunction that continues, or first appears, after a serotonergic antidepressant has been discontinued. The drugs most often implicated are SSRIs and serotonin-norepinephrine reuptake inhibitors (SNRIs), along with some tricyclics such as clomipramine and amitriptyline.
The distinction that matters is timing. Delayed ejaculation and reduced libido during treatment are common and usually reversible. PSSD is the situation where that reversal does not happen.
Two related conditions are discussed alongside it. Persistent sexual dysfunction has been reported after stopping finasteride, used for hair loss and prostate enlargement, and after isotretinoin, used for acne. All three drugs affect neurosteroid metabolism, which is one reason the conditions are studied together rather than separately.
Symptoms: genital numbness is the distinguishing feature
Reduced genital sensation is the symptom that separates PSSD from a depressive relapse. Patients describe touch as muted or anesthetic, sometimes with reduced nipple sensitivity as well. Depression does not typically produce a somatic sensory change of this kind.
The reported symptom set includes:
- Genital numbness or reduced genital sensation
- Orgasm that is weak, delayed, or without pleasure
- Loss of sexual desire, including absence of sexual thoughts
- Erectile dysfunction, or reduced vaginal lubrication
- Emotional blunting and loss of sexual imagery
Onset follows two patterns. In most reported cases, symptoms begin during treatment and simply fail to resolve after the drug is stopped. In a smaller group, symptoms appear or worsen only after discontinuation, which is the pattern patients find hardest to connect to a medication they are no longer taking. Both patterns fall within the published criteria.
Emotional blunting deserves a separate note because it is easy to misread. In depression, flattened emotion arrives with low mood, guilt, and loss of interest across all activities. In PSSD, mood has often improved while sensation and sexual response have not returned. That dissociation between mood and sensation is a useful clinical signal.
How common is PSSD?
Prevalence estimates differ by more than an order of magnitude, and the disagreement is informative in itself.
| Study design | Reported frequency | Interpretation |
| Retrospective cohort, Israeli health database (2023) | About 1 in 216 men treated with serotonergic antidepressants (0.46%) | Defined by phosphodiesterase type 5 inhibitor prescriptions, so sensory symptoms are not captured |
| Cross-sectional survey, North American youth (2025) | 13.2% of past antidepressant users vs 0.9% of other medication users | Self-reported; sample was sexual and gender minority youth aged 15 to 29 |
| Systematic review (2023) | Concluded that accurate prevalence estimates are not currently possible | No prospective study has applied the diagnostic criteria |
The spread comes from what each study counts. A prescription-based definition captures erectile dysfunction and misses genital numbness entirely. A symptom questionnaire captures numbness but cannot separate drug effect from other causes. Until a prospective cohort applies the published criteria, the honest answer is that the frequency is unknown but not negligible.
The 2025 survey is worth reading carefully rather than quoting as a headline figure. It reported an adjusted odds ratio of 14.2 with a confidence interval running from 2.92 to 257, which signals a real association measured with very little precision.
Underreporting compounds the problem in a way that is specific to this condition. A 2024 commentary in Epidemiology and Psychiatric Sciences set out the obstacles: patients are reluctant to raise sexual complaints, clinicians frequently respond in ways that close the conversation, and many people never connect a current symptom to a drug they stopped taking months earlier. Any figure derived from spontaneous reporting will therefore be an undercount by an unknown margin.
What might cause it
No mechanism is established. Three hypotheses are being tested in parallel.
The first is persistent desensitization of the 5-HT1A serotonin receptor. Prolonged serotonergic stimulation may leave the receptor unable to return to its prior responsiveness after the drug is cleared.
The second involves neurosteroids. Serotonergic drugs appear to reduce 5-alpha-reductase activity, lowering allopregnanolone and related neurosteroids that modulate sexual response. This hypothesis has the advantage of explaining why finasteride, a direct 5-alpha-reductase inhibitor, is associated with a similar syndrome.
The third concerns downstream changes in dopaminergic reward circuits, possibly epigenetic, along with altered transient receptor potential ion channel function in peripheral sensory nerves. The peripheral component is what the sensory symptoms point toward, since numbness confined to the genital area and nipples is difficult to explain through central mechanisms alone.
Most of this evidence comes from animal work and small case series. None of it demonstrates causation in humans, and the competing hypotheses are not mutually exclusive. A condition combining sensory loss, absent desire, and emotional blunting may well involve central and peripheral changes at the same time.
The 2022 diagnostic criteria
In 2022, a multidisciplinary international panel published criteria in the International Journal of Risk and Safety in Medicine. Three elements form the core.
Sexual function must have been normal before drug exposure. A change must have begun during or shortly after exposure. And symptoms must persist for at least three months after discontinuation.
Diagnosis is clinical. There is no confirmatory test, no biomarker, and no imaging finding. The criteria exist to make clinical description consistent and to make research comparable, not to replace assessment.
A clinical terminology code for PSSD was added to SNOMED CT in 2024, which allows the condition to be recorded formally in electronic health records. The condition is not yet in ICD-11.
What has to be ruled out first
Because diagnosis rests on exclusion, skipping the workup risks missing a treatable cause. A reasonable evaluation covers the following.
- Depressive relapse or residual symptoms. The most common alternative explanation, and the one most often mistaken for PSSD.
- Endocrine causes. Testosterone deficiency, thyroid dysfunction, and hyperprolactinemia are checked with straightforward blood tests.
- Vascular erectile dysfunction. Diabetes, hypertension, dyslipidemia, and smoking produce erectile dysfunction that has nothing to do with prior antidepressant use.
- Neurological causes. Pelvic surgery, trauma, and peripheral neuropathy can produce genital sensory loss.
- Other current medications. Antipsychotics, beta blockers, and 5-alpha-reductase inhibitors all affect sexual function.
In practical terms, the first visit usually involves a detailed medication timeline, a review of current symptoms by phase of the sexual response cycle, and blood tests covering morning total testosterone, thyroid-stimulating hormone, prolactin, fasting glucose or HbA1c, and a lipid panel. Penile duplex ultrasound or sensory testing may be added when vascular or neurological causes are suspected. Blood work and a careful history resolve a substantial proportion of cases. If a correctable cause is found, that is what gets treated.
What treatments have been tried
There is no approved treatment and no guideline. The published literature consists largely of case reports and small series with inconsistent results.
Agents that have been tried include bupropion, vortioxetine, trazodone, tadalafil, dopamine agonists, and various nutraceuticals. Low-power laser irradiation improved genital anesthesia in a single reported case, which is interesting but not a basis for practice. Sildenafil and testosterone supplementation failed to reverse symptoms in other reports, and sequential trials of bupropion, cabergoline, and selegiline were unsuccessful in one documented case.
Cognitive behavioral therapy has been proposed, mainly to address the distress and relationship strain that accompany the condition rather than to reverse the sensory changes.
The state of this evidence should be stated plainly. Case reports establish that something happened in one person; they cannot establish that a treatment works, and they systematically favor publication of successes over failures. Nothing in the current PSSD literature meets the standard of a controlled trial. Patients encountering confident treatment claims online should treat them accordingly.
In practice, management runs on two tracks. Treat whatever the exclusion workup identifies. Beyond that, the realistic goal is working with remaining function and addressing the psychological consequences, while being honest that no intervention has demonstrated reversal.
Relapse of depression during this period is not unusual. Agents with less serotonergic activity are generally preferred if antidepressant treatment has to resume, though there is no evidence that this choice improves an already established PSSD. The two problems are better managed separately.
Regulatory recognition and informed consent
In 2019, the European Medicines Agency recommended that product information for SSRIs and SNRIs reflect the possibility of sexual dysfunction persisting after discontinuation. Health Canada conducted a comparable safety review, and other national regulators have since issued similar communications.
No preventive strategy is known. Gradual tapering, which reduces discontinuation symptoms, has not been shown to prevent PSSD. Adding bupropion during treatment does not appear to prevent it either.
What remains is disclosure and early attention. Sexual side effects should be discussed before an antidepressant is started, and changes that appear during treatment should be raised rather than tolerated silently.
One point of proportion belongs here. PSSD appears to be uncommon, while the harms of untreated depression are common and well documented. The purpose of naming this condition is to give affected people a diagnosis and a pathway to care, not to discourage antidepressant treatment.
When to seek assessment
Symptoms that persist beyond three months after stopping a serotonergic antidepressant warrant evaluation. Start with the clinician who prescribed the medication, since the exclusion workup begins with history and blood tests.
Referral to a urologist is appropriate when genital sensory loss or erectile dysfunction is the dominant complaint. Continued involvement of a psychiatrist matters as well, because distinguishing residual depression from PSSD is central to the diagnosis and because the distress associated with this condition is substantial.
Key takeaways
- PSSD is sexual dysfunction persisting more than three months after stopping a serotonergic antidepressant, with reduced genital sensation as its most distinguishing feature.
- Prevalence estimates range from roughly 0.46% to 13% depending entirely on study design, and no reliable population figure exists.
- Diagnosis is clinical and requires excluding depressive relapse, endocrine, vascular, and neurological causes first.
- No treatment has demonstrated reversal; management focuses on correctable contributors and on psychological support.
If symptoms have persisted after discontinuation, ask for an evaluation rather than waiting to see whether they resolve on their own.
Frequently asked questions
Does PSSD improve over time?
Some people report partial recovery over months to years. The proportion who recover fully, and the proportion in whom symptoms are permanent, have not been established in any systematic study.
Can it happen after only a short course of treatment?
Cases have been reported following brief exposure. A relationship between dose, duration, and risk has not been demonstrated, which is one of the open questions the systematic reviews highlight.
Is PSSD just relapsed depression?
The two overlap and can coexist, which is why exclusion matters. Genital sensory loss is not a feature of depression, and mood improving while sexual sensation does not is the pattern that points away from relapse.
Does it affect women as well?
Yes. Loss of desire, orgasmic difficulty, reduced lubrication, and genital sensory loss are all reported. Women are underrepresented in adverse event databases, so published figures likely understate the true frequency.
Should I avoid antidepressants because of this risk?
That decision belongs with your clinician and depends on how severe your depression is and what alternatives exist. The point of knowing about PSSD is informed consent and early recognition, not avoidance of effective treatment.
References
- Healy D, Bahrick A, Bak M, et al. Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin. Int J Risk Saf Med 2022;33:65-76.
- Tarchi L, Merola GP, Baccaredda-Boy O, et al. Selective serotonin reuptake inhibitors, post-treatment sexual dysfunction and persistent genital arousal disorder: a systematic review. Pharmacoepidemiol Drug Saf 2023;32:1053-67.
- Ben-Sheetrit J, Hermon Y, Birkenfeld S, et al. Estimating the risk of irreversible post-SSRI sexual dysfunction (PSSD) due to serotonergic antidepressants. Ann Gen Psychiatry 2023;22:15.
- Pirani Y, Delgado-Ron JA, Marinho P, et al. Frequency of self-reported persistent post-treatment genital hypoesthesia among past antidepressant users: a cross-sectional survey of sexual and gender minority youth in Canada and the US. Soc Psychiatry Psychiatr Epidemiol 2025;60:1771-9.
- Healy D, Mangin D. Post-SSRI sexual dysfunction: barriers to quantifying incidence and prevalence. Epidemiol Psychiatr Sci 2024;33:e40.
This article is intended as general medical information and does not replace individual diagnosis or treatment. Do not adjust prescribed medication on your own. If you have symptoms, please consult a qualified healthcare professional.
Leave a Reply